AR043379A1 - Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k - Google Patents
Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-kInfo
- Publication number
- AR043379A1 AR043379A1 ARP040100573A ARP040100573A AR043379A1 AR 043379 A1 AR043379 A1 AR 043379A1 AR P040100573 A ARP040100573 A AR P040100573A AR P040100573 A ARP040100573 A AR P040100573A AR 043379 A1 AR043379 A1 AR 043379A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- maxi
- pten
- disease
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44943503P | 2003-02-25 | 2003-02-25 | |
| US44958903P | 2003-02-26 | 2003-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043379A1 true AR043379A1 (es) | 2005-07-27 |
Family
ID=32930512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100573A AR043379A1 (es) | 2003-02-25 | 2004-02-24 | Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7825130B2 (https=) |
| EP (1) | EP1599205B1 (https=) |
| JP (3) | JP4590397B2 (https=) |
| KR (1) | KR101031163B1 (https=) |
| CN (2) | CN1780623B (https=) |
| AR (1) | AR043379A1 (https=) |
| AT (1) | ATE345800T1 (https=) |
| AU (1) | AU2004216340B9 (https=) |
| BR (1) | BRPI0407832A (https=) |
| CA (1) | CA2515590C (https=) |
| CY (1) | CY1106294T1 (https=) |
| DE (1) | DE602004003348T2 (https=) |
| DK (1) | DK1599205T3 (https=) |
| ES (1) | ES2276282T3 (https=) |
| MX (1) | MXPA05008996A (https=) |
| MY (1) | MY136863A (https=) |
| PT (1) | PT1599205E (https=) |
| TW (1) | TWI323660B (https=) |
| WO (1) | WO2004075897A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI323660B (en) * | 2003-02-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Pten inhibitor or maxi-k channels opener |
| TW200848041A (en) * | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
| KR101441725B1 (ko) * | 2007-05-22 | 2014-09-18 | 오츠카 세이야쿠 가부시키가이샤 | 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제 |
| AR067746A1 (es) * | 2007-08-02 | 2009-10-21 | Otsuka Pharma Co Ltd | Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol |
| CN101932331B (zh) * | 2008-01-17 | 2012-10-24 | 刘奎 | 卵泡体外成熟方法 |
| AR070816A1 (es) * | 2008-03-14 | 2010-05-05 | Otsuka Pharma Co Ltd | Farmaco de combinacion para tratar trastornos vasculares |
| WO2009117387A2 (en) * | 2008-03-17 | 2009-09-24 | The Trustees Of Columbia University In The City Of New York | Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway |
| US8367352B2 (en) | 2008-06-06 | 2013-02-05 | Children's Medical Center Corporation | Promoting axon regeneration in the adult CNS through control of protein translation |
| WO2011044701A1 (en) | 2009-10-16 | 2011-04-21 | The University Of British Columbia | Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| EP2773382A4 (en) | 2011-11-01 | 2016-03-23 | Childrens Medical Center | SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION |
| RU2015101100A (ru) | 2012-06-15 | 2016-08-10 | Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн | Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения |
| JP2016040542A (ja) * | 2014-08-13 | 2016-03-24 | 学校法人金沢医科大学 | 認知症治療薬または認知症治療薬候補物質のスクリーニング方法 |
| JP2017070404A (ja) * | 2015-10-06 | 2017-04-13 | アンディ チャオ | トイレ床面の清潔な芳香パッド |
| WO2017199755A1 (ja) * | 2016-05-19 | 2017-11-23 | 国立研究開発法人国立循環器病研究センター | 認知症の予防及び/又は治療のための薬剤 |
| WO2021230131A1 (ja) * | 2020-05-11 | 2021-11-18 | 株式会社島津製作所 | 軽度認知障害治療剤 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535019A (en) * | 1978-09-01 | 1980-03-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JPS5649378A (en) * | 1979-08-25 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Tetrazolylalkoxycarbostyril derivative |
| JPH0653666B2 (ja) | 1990-10-22 | 1994-07-20 | 大塚製薬株式会社 | ヒトの糖尿病性知覚障害および末梢神経障害の治療剤 |
| JPH0614444A (ja) * | 1992-06-25 | 1994-01-21 | Central Japan Railway Co | 電力ケーブル接続部の固定装置 |
| JPH06239745A (ja) * | 1992-12-24 | 1994-08-30 | Otsuka Pharmaceut Co Ltd | 乾癬治療剤 |
| AU5715994A (en) * | 1992-12-24 | 1994-07-19 | Otsuka Pharmaceutical Co., Ltd. | Psoriasis remedy |
| JPH0776584A (ja) | 1993-09-07 | 1995-03-20 | Otsuka Pharmaceut Co Ltd | 内皮細胞障害抑制剤 |
| JP3944257B2 (ja) | 1995-12-07 | 2007-07-11 | 大塚製薬株式会社 | 肝実質細胞増殖因子産生増加剤 |
| US6322524B1 (en) * | 1997-08-28 | 2001-11-27 | Visco Technologies, Inc. | Dual riser/single capillary viscometer |
| US6019735A (en) * | 1997-08-28 | 2000-02-01 | Visco Technologies, Inc. | Viscosity measuring apparatus and method of use |
| US6322525B1 (en) * | 1997-08-28 | 2001-11-27 | Visco Technologies, Inc. | Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity |
| US6428488B1 (en) * | 1997-08-28 | 2002-08-06 | Kenneth Kensey | Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids |
| US6187790B1 (en) * | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
| MXPA00010254A (es) * | 1998-05-01 | 2002-08-06 | R Cutler Neal | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6257985B1 (en) * | 1999-10-01 | 2001-07-10 | Rexnord Corporation | Global shaft coupling |
| US6484565B2 (en) * | 1999-11-12 | 2002-11-26 | Drexel University | Single riser/single capillary viscometer using mass detection or column height detection |
| JP4159224B2 (ja) | 2000-02-29 | 2008-10-01 | 三洋電機株式会社 | 食器洗浄機 |
| US6458804B1 (en) * | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
| US6743806B2 (en) * | 2002-10-23 | 2004-06-01 | Otsuka Pharmaceutical Company, Limited | Active oxygen scavenger |
| TWI323660B (en) * | 2003-02-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Pten inhibitor or maxi-k channels opener |
-
2004
- 2004-02-11 TW TW093103143A patent/TWI323660B/zh not_active IP Right Cessation
- 2004-02-17 MY MYPI20040511A patent/MY136863A/en unknown
- 2004-02-24 ES ES04713984T patent/ES2276282T3/es not_active Expired - Lifetime
- 2004-02-24 US US10/546,632 patent/US7825130B2/en not_active Expired - Fee Related
- 2004-02-24 MX MXPA05008996A patent/MXPA05008996A/es active IP Right Grant
- 2004-02-24 AU AU2004216340A patent/AU2004216340B9/en not_active Ceased
- 2004-02-24 AR ARP040100573A patent/AR043379A1/es unknown
- 2004-02-24 PT PT04713984T patent/PT1599205E/pt unknown
- 2004-02-24 JP JP2006502683A patent/JP4590397B2/ja not_active Expired - Fee Related
- 2004-02-24 WO PCT/JP2004/002146 patent/WO2004075897A1/en not_active Ceased
- 2004-02-24 KR KR1020057015646A patent/KR101031163B1/ko not_active Expired - Fee Related
- 2004-02-24 CN CN2004800111403A patent/CN1780623B/zh not_active Expired - Fee Related
- 2004-02-24 DE DE602004003348T patent/DE602004003348T2/de not_active Expired - Lifetime
- 2004-02-24 BR BRPI0407832-2A patent/BRPI0407832A/pt not_active IP Right Cessation
- 2004-02-24 DK DK04713984T patent/DK1599205T3/da active
- 2004-02-24 CN CN201010130082.3A patent/CN101829116B/zh not_active Expired - Fee Related
- 2004-02-24 CA CA2515590A patent/CA2515590C/en not_active Expired - Fee Related
- 2004-02-24 AT AT04713984T patent/ATE345800T1/de active
- 2004-02-24 EP EP04713984A patent/EP1599205B1/en not_active Expired - Lifetime
-
2006
- 2006-12-19 CY CY20061101814T patent/CY1106294T1/el unknown
-
2009
- 2009-12-30 US US12/650,275 patent/US8329731B2/en not_active Expired - Fee Related
-
2010
- 2010-08-12 JP JP2010180661A patent/JP5208172B2/ja not_active Expired - Lifetime
-
2012
- 2012-11-07 US US13/671,448 patent/US8653104B2/en not_active Expired - Fee Related
-
2013
- 2013-01-10 JP JP2013002314A patent/JP5566482B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043379A1 (es) | Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k | |
| JP7041166B2 (ja) | トリアリールポリアミンを含む組成物および方法 | |
| SG159388A1 (en) | Antibacterial agents | |
| RU2010123052A (ru) | Авенантрамидсодержащие композиции | |
| CO6220955A2 (es) | Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida | |
| PE20110671A1 (es) | Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina | |
| NZ595448A (en) | Hydroxythienoquinolones and related compounds as anti-infective agents | |
| AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
| CL2009000695A1 (es) | Compuestos derivados de 6-fenil-imidazo[1,2-a]piridina sustituidos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; utiles para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, de traumatismos cerebrales y de la epilepsia, entre otras. | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP3197475B1 (en) | Compositions useful for the prevention and/or treatment of infections and inflammations | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| AR060089A1 (es) | Tratamiento del dolor | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| BRPI0410837A (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição | |
| GT200600160A (es) | Tratamiento del dolor | |
| AR044315A1 (es) | Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido | |
| MX2021009082A (es) | Compuestos quimicos. | |
| US10441588B2 (en) | Methods and compositions for treating bacterial infection | |
| EA201070898A1 (ru) | Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва | |
| WO2012038850A8 (en) | Pyrimidones for treatment of potassium channel related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |